Nomos IPO To Support Expanded Radiation Therapy Applications
This article was originally published in The Gray Sheet
Executive Summary
Nomos will pursue expanded indications for its IMRT Intensity Modulated Radiation Therapy technology for cancerous tumors with proceeds from a planned initial public offering, valued at up to $50 mil
You may also be interested in...
Financings In Brief
Guidant/Vesalius Ventures: Telemedicine and clinical informatics "seed-stage" venture capital funding opportunities will be the primary focus of Vesalius Ventures - formed by Guidant in partnership with Vanguard Ventures and Fremont Ventures, Guidant says. The convergence of medical and information technologies "offers opportunities to more effectively diagnose and treat patients with chronic diseases," Guidant Chief Information Officer William McConnell explains in a release. Separately, Guidant invests $10 mil. in privately held Cardica, Inc., developer of automated anastomosis technology for off-pump and on-pump coronary bypass surgery...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.